---
layout: post
title: 康希诺生物港股上涨，此前疫苗在加拿大获准进行临床试验
date: 2023-07-24 12:33:04.000000000 +08:00
link: https://cn.wsj.com/amp/articles/%E5%BA%B7%E5%B8%8C%E8%AF%BA%E7%94%9F%E7%89%A9%E6%B8%AF%E8%82%A1%E4%B8%8A%E6%B6%A8-%E6%AD%A4%E5%89%8D%E7%96%AB%E8%8B%97%E5%9C%A8%E5%8A%A0%E6%8B%BF%E5%A4%A7%E8%8E%B7%E5%87%86%E8%BF%9B%E8%A1%8C%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C-5dc35ef0
categories: wsj
---

<main id="main" role="main">
<div>


</div>
<div itemprop="articleLead" data-sbId="CN-BIZ-20230724115556">
    <div>
      <div class="media-object scope-
          header
">
          <figure>
      <div>
        <img
          srcset="https://images.wsj.net/im-698328?width=540&amp;size=1.5005861664712778 540w, https://images.wsj.net/im-698328?width=620&amp;size=1.5005861664712778 620w, https://images.wsj.net/im-698328?width=639&amp;size=1.5005861664712778 639w, https://images.wsj.net/im-698328?width=860&amp;size=1.5005861664712778 860w, https://images.wsj.net/im-698328?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=1.5 1290w, https://images.wsj.net/im-698328?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=2 1720w, https://images.wsj.net/im-698328?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=3 2580w"
          src="https://images.wsj.net/im-698328?width=860&amp;height=573"
          layout="responsive"
          placeholder
          alt="">
        </img>
      </div>
      <figcaption>
        <p>去年，在中国毕节，一名卫生工作者正在准备注射康希诺公司生产的吸入式新冠疫苗。</p>
    <p> 图片来源：Agence France-Presse/Getty Image</p>
  </figcaption>
</figure>

      </div>
    </div>
</div>
<div data-sbId="CN-BIZ-20230724115556">

<div>

  <div>
      <p> </p>
              <p><span itemprop="name">
                <a href="https://www.wsj.com/news/author/yifan-wang" itemprop="url" rel="author">Yifan Wang</a>
              </span></p>

  </div>
    <time>
      2023年7月24日12:05 CST 更新
    </time>
</div>

<div subscriptions-actions subscriptions-display="NOT data.noSharing">
  <div>
    <social-share type="system" width="72" height="24"
      data-param-url="https://cn.wsj.com/articles/康希诺生物港股上涨-此前疫苗在加拿大获准进行临床试验-5dc35ef0">
    </social-share>
  </div>
</div>


<div subscriptions-section="content">
</div>
<div subscriptions-section="content-not-granted">
</div>



<section subscriptions-section="content">
      <p>康希诺生物股份公司(CanSino Biologics, 6185.HK)在香港上市的股票上涨，这家中国生物技术公司的疫苗获得监管部门批准，令投资者信心大增。</p>
      <p>该股涨幅最高达8.2%，最新上涨4.8%，报26.35港元。</p>
      <p>康希诺生物在周日晚间表示，其与纳斯达克上市公司Vaccitech共同研发的重组带状疱疹疫苗获得了监管部门的绿灯，可以在加拿大开始临床试验。</p>
      <p>该公司说，加拿大卫生部门对该疫苗的临床试验发出了“无异议”函。该公司补充说，该疫苗的肌肉注射型和气雾吸入型都获准进行临床试验。</p>
      <div></div>
</section>

</div>
      </main>
